{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for beta root_polymer_monomers_monomerSubstance_refPname in Monomer Substance Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
OSCIMIN by Larken Laboratories, Inc.
(2011)
Source URL:
First approved in 1948
Source:
ANDA203002
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
21 CFR 358A
(1992)
Source URL:
First approved in 1941
Source:
ANDA203849
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT01586338: Phase 4 Interventional Completed Osteoarthritis
(2012)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT04645550: Phase 4 Interventional Completed Cirrhosis
(2020)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
Fraxiparine by Aspen Pharmacare Canada Inc. [Canada]
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Class:
POLYMER
Status:
Possibly Marketed Outside US
Source:
NCT00196417: Phase 4 Interventional Unknown status Heparin-Induced Thrombocytopenia
(2003)
Source URL:
Class:
POLYMER
Status:
Possibly Marketed Outside US
Class:
POLYMER
